Recall Alert: Cipla Albuterol Sulfate Inhalation Aerosol

Cipla Issues Voluntary Nationwide Recall of Six Batches of Albuterol Sulfate Inhalation Aerosol, 90 mcg (200 Metered Inhalation) Due to Container Defect For Immediate Release July 7, 2023 Contact Information Cipla Customer Service 844-247-5287 cipla.cs@cipla.com Company Announcement FOR IMMEDIATE RELEASE – Mumbai, India July 6, 2023/ New Jersey, USA July 6, 2023 – Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”), today announced that its wholly-owned…

Lesen Sie weiter auf: Recall Alert: Cipla Albuterol Sulfate Inhalation Aerosol
Quelle: Asthma and Allergy Foundation of America
Titelbild/Grafik by Asthma and Allergy Foundation of America (AAFA)

Kommentare und Fragen

Möchten Sie zu diesem Artikel ein Kommentar abgeben oder haben Sie dazu eine Frage, dann machen Sie dies bitte immer auf der Herausgeberseite!

Weiteres von Asthma and Allergy Foundation of America

• September Research Update: Asthma, HES, CSU, and Universal Flu Vaccine
• AAFA’s Statement on FDA Decision on neffy®, Epinephrine Nasal Spray
• FDA Panel Finds Popular Decongestant Doesn’t Work and FDA May Remove It From the Market
• Asthma Peak Month: The Factors Behind the Asthma Peak in September
• 2023 Asthma Capitals™ Report: Where Does Your City Rank?
• Could Your Nasal Polyps Benefit from a Biologic Medicine? – Webinar
• August Research Update: Asthma, CSU, Epinephrine, Meat Allergy, Long COVID, and More
• A Parent’s Guide to Asthma Care at School (Video)
• Viatris Announces Launch of Breyna™, the First FDA-Approved Generic Version of Symbicort®
• Kimberly Spencer-McLeod: Turning Pain Into Purpose